Tengion (TNGN) Stock Price, News & Analysis

Company Overview

Tengion, Inc. is a clinical-stage regenerative medicine company focused on the development and commercialization of autologous, organ regenerative therapies. Using its proprietary Neo-Organ platform, the company expands a patient’s own progenitor cells in vitro and incorporates them with biomaterial scaffolds to form living tissue constructs for implantation. Tengion’s pipeline has included product candidates such as Neo-Urinary Conduit, Neo-Bladder Augment and Neo-Kidney Augment, each designed to address unmet needs in urology and nephrology.

Founded in 2003 and headquartered in Redwood City, California, Tengion has advanced several first-of-kind clinical trials in collaboration with leading academic medical centers. The Neo-Urinary Conduit program progressed into Phase II studies in patients undergoing radical cystectomy for bladder cancer, while the Neo-Kidney Augment initiative targeted chronic kidney disease. Although some programs were later discontinued or restructured, these efforts helped establish the company’s expertise in cell-based organ regeneration.

Concentrated primarily in the United States, Tengion works closely with regulatory authorities to navigate the approval pathway for its innovative therapies. The company’s management team combines experience in regenerative medicine research, clinical development and commercial strategy. Trading on the OTC Markets under the ticker symbol TNGN, Tengion continues to seek partnerships and funding to support its mission of creating living tissues and organs for patients with limited treatment options.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 10,000 shs
• Average Volume: 6,051 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:TNGN
• CIK: 1296391
• Web: www.tengion.com
• Phone: (336) 722-5855
• Fax: N/A
• Employees: 25
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A